Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | RECQL | P46063 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethylamine SCHEMBL4087150 | 0.93 | GAA (0.54) | GAAHTTKMT2AKDM4EPOLB | |
| SCHEMBL2901212 | 0.86 | GAA (0.71) | GAAHTTKMT2AKDM4EPOLB | |
| SCHEMBL4094277 | 0.85 | GAA (0.65) | GAAHTTKMT2AKDM4EPOLB | |
| SCHEMBL9158980 | 0.85 | GAA (0.56) | GAAHTTKMT2AKDM4EPOLB | |
| SCHEMBL9150456 | 0.83 | GAA (0.48) | GAAHTTKMT2AKDM4EPOLB | |
| SCHEMBL1647940 | 0.83 | GAA (0.67) | GAAHTTKMT2AKDM4EPOLB | |
| SCHEMBL29494819 | 0.83 | GAA (0.58) | GAAHTTKMT2AKDM4EPOLB | |
| SCHEMBL28800695 | 0.83 | GAA (0.58) | GAAHTTKMT2AKDM4EPOLB | |
| SCHEMBL10079252 | 0.83 | GAA (0.58) | GAAHTTKMT2AKDM4EPOLB | |
| SCHEMBL9682135 | 0.83 | GAA (0.58) | GAAHTTKMT2AKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894339-A | 2-fluorobiphenyl-4-acetic acid derivative and preparation method and application thereof | 江苏普莱医药生物技术有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | INVITROGEN CORPORATION | 2016-10-27 | — | — | US | disclosed |
| EP-0608089-B1 | Phenylalkanoic acid esters and their use as antioxidants | SANKYO CO (JP) | 1997-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | GAA 364/4885HTT 3738/4885KMT2A 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.